Teva Innovative Medicine & Biosimilar Pipeline

By development stage – as of November 1, 2024

Download PDF

  • Novel Biologics
  • Small Molecules
  • Biosimilars

Under Regulatory Review

Biosimilar to Prolia®

(denosumab)
  • Biosimilars

Phase 3

More information

Phase 3 clinical trials are larger trials typically conducted with up to several thousand participants and are designed to establish if the intervention is safe and effective in preparation for product approval. The results show whether or not the intervention is beneficial to a particular group of participants.

Olanzapine LAI

(TEV-'749)
  • Innovative Medicines
  • Schizophrenia

ICS/SABA

(TEV-'248)
  • Innovative Medicines
  • Asthma

In collaboration with Launch Therapeutics.

Biosimilar to Entyvio®

(vedolizumab)
  • Biosimilars

In collaboration with Alvotech for the U.S. market.

Biosimilar to Eylea®

(aflibercept)
  • Biosimilars

In collaboration with Alvotech for the U.S. market.

Biosimilar to Xgeva®

(denosumab)
  • Biosimilars

Biosimilar to Xolair®

(omalizumab)
  • Biosimilars

Biosimilar to Simponi®

(golimumab)
  • Biosimilars

In collaboration with Alvotech for the U.S. market.

Biosimilar to Simponi Aria®

(golimumab)
  • Biosimilars

In collaboration with Alvotech for the U.S. market.

Phase 2

More information

Phase 2 clinical trials are conducted with up to several hundred participants. They are designed to collect additional information about whether the intervention is safe and effective. The results of these types of clinical trials may be used to design future trials or to develop additional research methods.

Duvakitug

(TEV-'574)
  • Innovative Medicines
  • Ulcerative Colitis, Crohn’s Disease

In collaboration with Sanofi.

Emrusolmin

(TEV- '286)
  • Innovative Medicines
  • Multiple System Atrophy

In collaboration with MODAG.

Phase 1

More information

Phase 1 clinical trials are small-scale clinical trials with very few participants to examine the way the intervention (e.g., medication) interacts with the human body. The purpose of the study is to collect information about the safety of the interventions assessed. These trials are typically conducted in healthy participants without a specific medical condition.

Anti-IL-15

(TEV-‘408)
  • Innovative Medicines
  • Celiac & Vitiligo

TEV-'192

  • Innovative Medicines
  • Immunology & Neuroscience

Anti-PD1-IL2

TEV-’278
  • Innovative Medicines
  • Attenukine Oncology

Pre-clinical

More information

More information about this phase in drug development.

TEV-'6000

  • Innovative Medicines
  • Neuroscience

TEV-'279

  • Innovative Medicines
  • Neuroscience

TEV-'287

  • Innovative Medicines
  • Neuroscience

In collaboration with MODAG.

TEV-'288

  • Innovative Medicines
  • Neuroscience

TEV-'285

  • Biosimilars

TEV-'261

  • Biosimilars

TEV-'294

  • Biosimilars

In collaboration with Alvotech for the U.S. market.

TEV-'289

  • Biosimilars

TEV-'292

  • Biosimilars

In collaboration with Alvotech for the U.S. market.

TEV-'295

  • Biosimilars

In collaboration with Alvotech for the U.S. market.

TEV-'296

  • Biosimilars

In collaboration with Alvotech for the U.S. market.

TEV-'316

  • Biosimilars

In collaboration with mAbxience.

TEV-‘333

  • Biosimilars

In collaboration with mAbxience.

No drugs found for your filtering criteria

Your filtering criteria did not match any drugs we currently have in the pipeline. Reset filters to see all drugs or modify your filtering criteria.

Reset Filters

Teva innovative medicine and biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Pipeline is current as of November 1, 2024.